NCT05454774View on ClinicalTrials.gov

A Study of FVIII Gene Therapy for Hemophilia A

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

December 15, 2024

Study Completion Date

September 15, 2027

Conditions
Hemophilia A
Interventions
GENETIC

Single dose intravenous injection of BBM 002

Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10\^13 vg/ kg

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER